CLAIM AMENDMENTS

- 1. (Previously Presented) A method for inducing an immune response against an antigen in a mammal, which method comprises:
 - (i) inoculating the mammal with a first recombinant vector comprising a nucleic acid insert encoding an antigen; and
 - (ii) inoculating the mammal with a second recombinant vector comprising a nucleic acid insert encoding said antigen, the first recombinant vector is different from the second recombinant vector, thereby inducing an immune response against said antigen in the mammal.
- 2. (Previously Presented) The method according to claim 1, wherein the first recombinant vector is a recombinant vaccinia viral vector.
- 3. (Previously Presented) The method according to claim 1, wherein the first recombinant vector is a recombinant fowlpox viral vector.
- 4. (Previously Presented) The method according to claim 1, wherein the first recombinant vector is a recombinant adenoviral vector.
- 5. (Previously Presented) The method according to claim 1, wherein the nucleic acid inserts of the first and second recombinant vectors encoding said antigen further comprises a nucleic acid sequence encoding an immunostimulatory protein other than said antigen against which an immune response is to be induced.
- 6. (Previously Presented) The method according to claim 1, wherein the second recombinant vector is a recombinant vector.
- 7. (Previously Presented) The method according to claim 1, wherein the second recombinant vector is a recombinant fowlpox viral vector.
- 8. (Previously Presented) The method according to claim 1, wherein the second recombinant vector is a recombinant adenoviral vector.

9.-20. (Canceled)

In re Appln. of Chamberlain et al. Application No. 09/838,987

- 21. (Previously Presented) The method of claim 1, wherein said antigen is a tumor-associated antigen.
- 22. (Previously Presented) The method of claim 5, wherein said antigen is a tumor-associated antigen.
 - 23. (Canceled)